On Thursday afternoon, experts gathered by the Food and Drug Administration recommended a booster for older and more at-risk Americans who had originally received the Moderna Covid 19 vaccine. The unanimous vote will pave the way for the expected booster approval from the FDA and the Centers for Disease Control and Prevention. Unlike the recently approved booster for the Pfizer / BioNTech vaccine, however, Moderna’s booster will come as a half dose.
Experts outside the FDA’s Vaccine Advisory Committee met Thursday and are meeting again tomorrow to address long-standing questions about booster diets for Americans. Although Pfizer booster was food. Authorized For more than 65 people and high-risk individuals last month, it only covered people who had actually received the Pfizer vaccine.
Thursday’s meeting was about the modern vaccine. They are based on mRNA technology like Shot Pfizer, and they seem to have a similar effect in preventing death and disease from the corona virus. But less real-world data has been collected on modern vaccines than Pfizer, even just a week after Pfizer was shot in the United States last winter (in August this year, Pfizer’s vaccine was completed by the FDA). Became the first to receive approval).
Panel experts were concerned about the lack of real-world data supporting modern booster shots, compared to data available on Pfizer (in Israel, Pfizer booster has been available for months). Modern presented data from a small booster diet study. The New York Times reported., Which found that people’s antibody levels in the corona virus increased after receiving the booster. But experts also noted many similarities between the two vaccines, and, with the data to date, as well as Pfizer’s first departure, they concluded that there was no reason to reject Moderna’s application. Is.
“In some ways I support this EUA because we have already approved it for Pfizer and I don’t see how we can’t approve it for potentially modern, and most Americans are completely confused. I don’t fall. ” Stanley Perlman, professor of pediatrics at the University of Iowa and a member of the committee, during the meeting.
Although there are some subtle differences between the two vaccines, there are potentially significant differences. Unlike Pfizer, Moderna did not try to argue that a booster would be needed to prevent a weakening of the immune system against serious illness and hospitalization. Some data suggest that modern vaccines are more potent over time, possibly due to higher doses. This is an overdose which is why Moderna halved the dose for the booster. There is mixed evidence as to whether the immunity provided by the vaccine for Covid 19 has been significantly reduced in the general population, although there is now a strong evidence of loss in older people who took shots last winter. Is the case
The recommendations of these advisory committees do not automatically become policy, although the FDA rarely agrees with them. So for now, it is possible that booster mRNA vaccines will be preferred for people over the age of 65 and high-risk groups, such as people with compromised immune systems and health care workers who Can become infected more often. But it is not yet clear what the J&J vaccine will decide tomorrow, which has generally shown little effect as a single dose. The panel’s experts will not only discuss whether J&J booster is needed, but whether these booster doses should be given two months or six months after.